Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G-Protein Coupled Receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. With our proprietary GEODe platform, we aim to unlock the therapeutic utility of the most difficult receptors in the class, to date considered undruggable with small molecules. For more information, please visit www.tectonictx.com, or follow us on LinkedIn.